Valizadeh Osalo M, Hosseini P, Charkhian H, Soltanzadeh H, Goharkhany S, Tuncer S
Discov Oncol. 2024; 15(1):59.
PMID: 38433141
PMC: 10909800.
DOI: 10.1007/s12672-024-00919-z.
Karami S, Sattarifard H, Kiumarsi M, Sarabandi S, Taheri M, Hashemi M
Asian Pac J Cancer Prev. 2020; 21(10):3115-3123.
PMID: 33112575
PMC: 7798179.
DOI: 10.31557/APJCP.2020.21.10.3115.
Muhseen Z, Li G
Molecules. 2020; 25(1).
PMID: 31906032
PMC: 6983034.
DOI: 10.3390/molecules25010155.
Singh S, Vaughan C, Rabender C, Mikkelsen R, Deb S, Palit Deb S
JCI Insight. 2019; 4(20).
PMID: 31527309
PMC: 6824310.
DOI: 10.1172/jci.insight.128194.
Zou X, Zhang Y, Zhang L, Li J, Zhu C, Cheng Q
Medicine (Baltimore). 2018; 97(49):e13273.
PMID: 30544386
PMC: 6310604.
DOI: 10.1097/MD.0000000000013273.
Role of screening colonoscopy for colorectal tumors in Helicobacter pylori-related chronic gastritis with MDM2 SNP309 G/G homozygous: A prospective cross-sectional study in Thailand.
Tongtawee T, Simawaranon T, Wattanawongdon W
Turk J Gastroenterol. 2018; 29(5):555-560.
PMID: 30260777
PMC: 6284615.
DOI: 10.5152/tjg.2018.17608.
Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated and MDM2 up-regulation.
Tracz-Gaszewska Z, Klimczak M, Biecek P, Herok M, Kosinski M, Olszewski M
Oncotarget. 2017; 8(47):82123-82143.
PMID: 29137250
PMC: 5669876.
DOI: 10.18632/oncotarget.18899.
Lack of an Association between a Functional Polymorphism in the Promoter and Breast Cancer in Women in Northeast Iran.
Tavakkol Afshari Z, Nikpoor A, Tavakkol Afshari J, Ganjali R, Sanglakh Ghoochan Atigh P, Homaei Shandiz F
Rep Biochem Mol Biol. 2017; 6(1):112-117.
PMID: 29090237
PMC: 5643450.
Cathepsin-Mediated Cleavage of Peptides from Peptide Amphiphiles Leads to Enhanced Intracellular Peptide Accumulation.
Acar H, Samaeekia R, Schnorenberg M, Sasmal D, Huang J, Tirrell M
Bioconjug Chem. 2017; 28(9):2316-2326.
PMID: 28771332
PMC: 5937119.
DOI: 10.1021/acs.bioconjchem.7b00364.
Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53.
Senturk J, Bohlman S, Manfredi J
Oncogene. 2017; 36(44):6085-6096.
PMID: 28692049
PMC: 5987529.
DOI: 10.1038/onc.2017.229.
Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer.
Hashemi M, Amininia S, Ebrahimi M, Simforoosh N, Basiri A, Ziaee S
Oncol Lett. 2017; 13(4):2483-2489.
PMID: 28454424
PMC: 5403193.
DOI: 10.3892/ol.2017.5739.
MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients.
Varmazyar S, Marashi S, Shoja Z, Tornesello M, Buonaguro F, Shahmahmoodi S
Med Microbiol Immunol. 2017; 206(2):157-163.
PMID: 28083704
DOI: 10.1007/s00430-016-0491-9.
Influence of polymorphisms on squamous cell carcinoma susceptibility: a meta-analysis.
Yu H, Li H, Zhang J, Liu G
Onco Targets Ther. 2016; 9:6211-6224.
PMID: 27785069
PMC: 5067019.
DOI: 10.2147/OTT.S113417.
Copy number variation of E3 ubiquitin ligase genes in peripheral blood leukocyte and colorectal cancer.
Bi H, Tian T, Zhu L, Zhou H, Hu H, Liu Y
Sci Rep. 2016; 6:29869.
PMID: 27417709
PMC: 4945909.
DOI: 10.1038/srep29869.
Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects.
Yang X, Zhu Y, Ye D, Liu Y, Sun H, Ruan M
Mol Clin Oncol. 2016; 5(1):175-180.
PMID: 27330794
PMC: 4906982.
DOI: 10.3892/mco.2016.868.
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.
Wasylishen A, Lozano G
Cold Spring Harb Perspect Med. 2016; 6(8).
PMID: 27329033
PMC: 4968169.
DOI: 10.1101/cshperspect.a026211.
Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
Enokida Y, Shimizu K, Atsumi J, Kakegawa S, Takase Y, Kaira K
Cancer Med. 2016; 5(8):1791-801.
PMID: 27228500
PMC: 4884639.
DOI: 10.1002/cam4.750.
The Role of MDM2 Amplification and Overexpression in Tumorigenesis.
Oliner J, Saiki A, Caenepeel S
Cold Spring Harb Perspect Med. 2016; 6(6).
PMID: 27194168
PMC: 4888815.
DOI: 10.1101/cshperspect.a026336.
Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
Ding H, Dai Y, Ning Z, Fan N, Wang Z, Li P
Medicine (Baltimore). 2016; 95(12):e2941.
PMID: 27015167
PMC: 4998362.
DOI: 10.1097/MD.0000000000002941.
Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F, Corsini S, Gnoli M, Pedrini E, Mordenti M, Sangiorgi L
Fam Cancer. 2016; 15(4):635-43.
PMID: 26956143
DOI: 10.1007/s10689-016-9895-3.